Project Grant R44CA310319
Award Date 9/22/25
Completion Date 8/31/26
Dollars Obligated $315K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Lifengine Animal Health Laboratories Incorporated. The purpose of this Phase I grant is to demonstrate the feasibility of producing chimeric antigen receptor (CAR)-T cells that overexpress the transcription factor C-MYB to enhance their anti-tumor activity and limit functional exhaustion. Lifengine will leverage its proprietary GeneWeld gene editing platform to...
- The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $1,125,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Kure Ai Inc. located in Shaker Heights, Ohio. The grant will fund the development and clinical testing of an "ultra-fast" (less than 1 day) manufacturing process for chimeric antigen receptor (CAR) T cell therapies, a novel approach to treating relapsed/refractory cancers. The initial Phase 1 clinical trial of the...
- This $1,340,987 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Koi Biotherapeutics Inc. aims to revolutionize chimeric antigen receptor (CAR) T-cell therapy by developing a novel CAR-enhancer platform to improve the functionality and persistence of CAR T-cells. The key products and services to be delivered under this 2-year project include: Optimization of dosing and timing for CAR-enhancer administration in a Phase I clinical trial to enhance...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services National Institutes of Health, awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to Northwestern University. The grant aims to develop tunable, microenvironment-responsive CAR T cells using synthetic gene circuits to enhance the potency and safety of solid tumor CAR T cell therapy, with a focus on ovarian cancer. The key products or services to be...
- The National Cancer Institute (NCI), through the Cancer Treatment Research program (CFDA 93.395), awarded Cambium Oncology LLC a $400,835 project grant to develop a novel armored CAR-T immunotherapeutic for the treatment of pancreatic ductal adenocarcinoma (PDAC). The key focus of this 1-year project is to engineer CAR-T cells that can secrete an optimized form of a VIP receptor antagonist (ANT308-Fc) to disrupt the immunosuppressive tumor microenvironment of PDAC and enhance the anti-tumor...
- The National Cancer Institute (NCI), part of the National Institutes of Health, awarded Mucommune LLC a $1,146,618 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop in vivo-engineered multi-functional B7H3-targeted CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma. The project aims to leverage Mucommune's novel platform that can specifically transduce non-activated T-cells with chimeric antigen receptors (CAR) in vivo, eliminating the...
- The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,031,566 to Mucommune LLC to develop an in vivo engineering approach for generating B7-H3-targeted CAR-T cells for ovarian cancer therapy. The goal is to directly transduce circulating T-cells with a Nipah virus-based lentiviral vector system, enabling the production of potent CAR-T cells without the need for ex vivo cell processing. This novel platform aims to reduce the time and...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,444 Project Grant to Cancure LLC (DBA Canzx Biotherapeutics) to conduct a feasibility study of a novel NK and CD8 T cells stimulating agent. The project aims to develop a complex molecule that can be used as an additive during NK and antigen-specific CD8 T cell expansion to enable their superior efficacy in treating solid tumors. The key objectives are to address the challenges of persistence and...
- The National Cancer Institute (NCI), under the federal Cancer Treatment Research Program (CFDA 93.395), has awarded a $276,544 project grant to Ioncologi Inc. to develop IOI7, a therapy utilizing autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cells (HSC), for the treatment of immune checkpoint inhibitor (ICI)-resistant glioblastoma. The grant will fund two phases of the project: 1) Optimizing a closed, scalable, and commercially viable HSC expansion manufacturing platform; and...